Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.31 is 22% below its 5-year average of -1.08, near the low end of its 5-year range (-1.51–0.00).
7.82% below its 12-month average of -1.22.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.30.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.31
EARNINGS PER SHARE (EPS) AVG TTM
-1.22
EARNINGS PER SHARE (EPS) AVG 3Y
-1.34
EARNINGS PER SHARE (EPS) AVG 5Y
-1.08
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.82%
CURRENT VS 3Y AVG
+2.42%
CURRENT VS 5Y AVG
-21.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Nuvectis Pharma, Inc.
Market Cap
$536.04M
Earnings Per Share (EPS)
-1.31
TTM Avg
-1.22
3Y Avg
-1.34
5Y Avg
-1.08
Market Cap
$536.32M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.57
3Y Avg
-0.87
5Y Avg
-0.89
Market Cap
$535.43M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$541.33M
Earnings Per Share (EPS)
-0.51
TTM Avg
-1.09
3Y Avg
-1.66
5Y Avg
-1.43
Market Cap
$543.65M
Earnings Per Share (EPS)
-1.28
TTM Avg
-4.16
3Y Avg
-4.49
5Y Avg
-4.33
Market Cap
$548.99M
Earnings Per Share (EPS)
-2.34
TTM Avg
-1.60
3Y Avg
-1.16
5Y Avg
-0.99
Market Cap
$526.07M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.82
3Y Avg
-0.78
5Y Avg
-1.65
Market Cap
$523.04M
Earnings Per Share (EPS)
-0.58
TTM Avg
-1.12
3Y Avg
-1.21
5Y Avg
-1.27
Market Cap
$522.16M
Earnings Per Share (EPS)
-0.78
TTM Avg
-1.17
3Y Avg
-1.45
5Y Avg
-1.68
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $536.04M | -1.31 | -1.22 | -1.34 | -1.08 |
| ProKidney Corp. (PROK)vs › | $536.32M | -0.57 | -0.57 | -0.87 | -0.89 |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | 0.01 | 0.08 | -2.02 | -4.00 |
| Shattuck Labs, Inc. (STTK)vs › | $541.33M | -0.51 | -1.09 | -1.66 | -1.43 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $543.65M | -1.28 | -4.16 | -4.49 | -4.33 |
| Monopar Therapeutics Inc. (MNPR)vs › | $548.99M | -2.34 | -1.60 | -1.16 | -0.99 |
| Immix Biopharma, Inc. (IMMX)vs › | $526.07M | -0.88 | -0.82 | -0.78 | -1.65 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $523.04M | -0.58 | -1.12 | -1.21 | -1.27 |
| Altimmune, Inc. (ALT)vs › | $522.16M | -0.78 | -1.17 | -1.45 | -1.68 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $520.33M | N/A | -1.57 | -1.57 | -1.57 |
Trailing EPS (TTM)
$-1.31
Forward EPS (Est.)
$-1.04
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.32 |
| 2024-12-31 | -1.11 |
| 2023-12-31 | -1.43 |
| 2022-12-31 | -1.51 |
| 2021-12-31 | -1.09 |
| 2020-12-31 | 0.00 |
